BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 25023849)

  • 21. [Current therapeutic strategies for mantle cell lymphoma].
    Dreyling M; Schnaiter A; Schmidt C; Hoster E
    Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
    Dreyling M; Ferrero S;
    Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrating emerging treatment options in mantle cell lymphoma.
    Kahl BS; Fowler NH; Czuczman MS
    Clin Adv Hematol Oncol; 2013 Dec; 11(12 Suppl 19):1-15. PubMed ID: 24893155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents.
    Inamdar AA; Goy A; Ayoub NM; Attia C; Oton L; Taruvai V; Costales M; Lin YT; Pecora A; Suh KS
    Oncotarget; 2016 Jul; 7(30):48692-48731. PubMed ID: 27119356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
    Kahl BS; Gordon LI; Dreyling M; Gascoyne RD; Sotomayor EM
    Leuk Lymphoma; 2015; 56(9):2505-11. PubMed ID: 25944379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma.
    Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The current therapeutic scenario for relapsed mantle cell lymphoma.
    Ferrero S; Dreyling M
    Curr Opin Oncol; 2013 Sep; 25(5):452-62. PubMed ID: 23872784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of mantle cell lymphoma: key challenges and next steps.
    Williams ME; Dreyling M; Winter J; Muneer S; Leonard JP
    Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):336-46. PubMed ID: 21030346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
    El Halabi L; Ghez D; Ribrag V
    Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Salvage therapy in relapsed or refractory malignant lymphoma].
    Kashimura T; Murohashi I
    Nihon Rinsho; 2000 Mar; 58(3):699-703. PubMed ID: 10741149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies in the treatment of mantle cell lymphoma.
    Deng C; Lee S; O'Connor OA
    Clin Cancer Res; 2012 Jul; 18(13):3499-508. PubMed ID: 22700864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on mantle cell lymphoma.
    Maddocks K
    Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mantle Cell Lymphoma: Current and Emerging Treatment Strategies and Unanswered Questions.
    Diamond B; Kumar A
    Hematol Oncol Clin North Am; 2019 Aug; 33(4):613-626. PubMed ID: 31229158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should there be a standard therapy for mantle cell lymphoma?
    Smith MR
    Future Oncol; 2011 Feb; 7(2):227-37. PubMed ID: 21345142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
    William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
    Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
    Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E;
    Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous transplantation and management of younger patients with mantle cell lymphoma.
    Geisler CH
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current strategies in the treatment of advanced stage mantle cell lymphoma].
    Lenz G; Dreyling M; Unterhalt M; Hiddemann W
    Dtsch Med Wochenschr; 2004 Nov; 129(45):2429-33. PubMed ID: 15529247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous Stem Cell Transplant: Still the Standard for Fit Patients With Mantle Cell Lymphoma.
    Staton AD; Langston AA
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S96-S99. PubMed ID: 28760309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.